Infant Bronchiolitis Prevention Campaign 2025-2026

September 26, 2025 Jennifer Chen Health
News Context
At a glance
  • Here's a breakdown of the information provided about Beyfortus and Synagis, focusing ‍on recommendations and ⁣key points:
  • * Beyfortus is now the preferred option: For most infants, Beyfortus (nirsevimab) is recommended over Synagis (palivizumab) for preventing RSV (Respiratory Syncytial Virus) infection.
  • * Synagis remains a therapeutic option, especially for children ‍who are eligible for it.
Original source: mesvaccins.net

Here’s a breakdown of the information provided about Beyfortus and Synagis, focusing ‍on recommendations and ⁣key points:

Key Takeaways:

* Beyfortus is now the preferred option: For most infants, Beyfortus (nirsevimab) is recommended over Synagis (palivizumab) for preventing RSV (Respiratory Syncytial Virus) infection.
* simplified Administration: Beyfortus has a⁢ simpler injection schedule than Synagis.
* Availability: Beyfortus can be given directly in maternity wards shortly after birth for⁢ babies born from September 1, 2025, and is also available through doctors, midwives, and PMI (child protection services).
* cost: Administration in maternity is fully covered. Or else, health insurance covers up to 30%, with full coverage possible through C2S or ‍AME, and additional coverage from supplemental health insurance.

specific Recommendations:

  1. Infants (Born Feb-Aug 2025 – Catch-up & Sept 1, 2025 ⁢onwards ‍- Routine):

* Beyfortus is recommended as a catch-up for babies born between February and August 2025.* Beyfortus is recommended as a single dose directly after birth for babies born on or after September 1, 2025.

  1. Children Under 24 Months (Second RSV Season & Vulnerable):

* Beyfortus is recommended for children under 24 months who are entering their second RSV season and are considered vulnerable due to:
* Recent treatment (within the last 6 months) for bronchopulmonary dysplasia.
* congenital heart disease with hemodynamic repercussions.

Synagis (Palivizumab):

* Synagis remains a therapeutic option, especially for children ‍who are eligible for it.
* However, the CNPP (National Pediatrics Council) recommends prioritizing Beyfortus for those children due to its simpler administration and comparable safety profile.
* There haven’t been direct studies comparing the effectiveness of Beyfortus vs. Synagis.

In essence, Beyfortus is being ⁤positioned as the primary preventative measure against RSV for most infants, with Synagis remaining an option for specific cases.

Worth a look